Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01
Authors:
- Anders FomsgaardAFAnders Fomsgaard
- Ingrid KarlssonIKIngrid Karlsson
- Gregers GramGGGregers Gram
- Christian SchouCSChristian Schou
- Sheila TangSTSheila Tang
- Peter BangPBPeter Bang
- Ingrid KromannIKIngrid Kromann
- Peter AndersenPAPeter Andersen
- Lars Vibe AndreasenLALars Vibe Andreasen
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- CD4 + T cells support cytotoxic T lymphocyte priming by controlling lymph node inputProceedings of the National Academy of Sciences, 2011
- Therapeutic Immunization with HIV-1 Tat Reduces Immune Activation and Loss of Regulatory T-Cells and Improves Immune Function in Subjects on HAARTPLOS ONE, 2010
- Response definition criteria for ELISPOT assays revisitedCancer Immunology, Immunotherapy, 2010
- The immune response during acute HIV-1 infection: clues for vaccine developmentNature Reviews Immunology, 2009
- A Novel Liposome-Based Adjuvant CAF01 for Induction of CD8+ Cytotoxic T-Lymphocytes (CTL) to HIV-1 Minimal CTL Peptides in HLA-A*0201 Transgenic MicePLOS ONE, 2009
- Cationic Liposomes Formulated with Synthetic Mycobacterial Cordfactor (CAF01): A Versatile Adjuvant for Vaccines with Different Immunological RequirementsPLOS ONE, 2008
- Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugsNature Medicine, 2008
- Control of Viremia and Prevention of AIDS following Immunotherapy of SIV-Infected Macaques with Peptide-Pulsed BloodPLOS Pathogens, 2008
- HLA class I supertypes: a revised and updated classificationBMC Immunology, 2008
- The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomesImmunology, 2007